De-Novo vs. upgrade cardiac resynchronisation therapy device: Demographics, indications, response and outcomes
| Total Cohort N = 373 | Upgrades N = 79 | De Novo Implants N = 294 | P value | |
|---|---|---|---|---|
| Age (mean+/-SD) | 72.0+/-10.4 | 74.0 +/- 10.6 | 71.44 +/- 10.4 | 0.055 |
| Gender (male n,%) | 287 (76.9%) | 69 (87.3%) | 218 (74.1%) | 0.013 |
| Device (CRT-D n,%) | 182 (48.8%) | 39 (49.4%) | 143 (48.6%) | 0.909 |
| NYHA Class 3/4 (n,%)* | 324 (91.5%) | 74 (98.7%) | 250 (90.0%) | 0.028 |
| LVEF <35% (n,%)* | 364 (98.4%) | 76 (97.4%) | 288 (98.6%) | 0.458 |
| QRS >150 msec (n,%)* | 272 (77.1%) | 55 (78.6%) | 217 (76.7%) | 0.634 |
| Acute Response (n,%) | 132 (61.4%) | 23 (59.0%) | 109 (61.9%) | 0.731 |
| Long-term Response (n,%) | 101 (47.0%) | 11 (25.6%) | 90 (52.3%) | 0.002 |
| All-Cause Mortality Rate
(36 months) (%+/-SE) | 21.1%+/-2.6% | 25.6%+/-5.8% | 19.2%+/-2.9% | (Log-Rank) 0.043 |
| All-Cause First Hospitalisation (36 months) (%+/-SE) | 42.9%+/-3.3% | 46.7%+/-3.7% | 41.9%+/-4.2% | (Log-rank)0.096 |
↵* Percentage represents all recorded data
HF = Heart Failure, NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, ECG = Electrocardiogram